|
|
|
| Precision Radiopharmaceuticals With Ratio's Jack Hoppin, Ph.D. | Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic. What’s more, radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena. Business of Biotech sits with Jack Hoppin, CEO of Ratio Therapeutics, a company that’s well-positioned with a fresh Series B and the foundation of a tunable radiotherapeutic. Listen now! |
|
|
|
|
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act but cautions rare disease drug developers against sky high and inaccessible drug pricing practices. |
|
|
|
Dynavax found a new revenue stream during COVID and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs and his own journey to CEO role. |
|
|
|
| The Cure For The Cure | Traditional aseptic filling solutions can introduce contamination and variability. Advanced technologies can automate the filling process without direct human contact. |
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
